Browsing Tag
Day One Biopharmaceuticals
3 posts
Servier bets $2.5bn on pediatric cancer specialist Day One Biopharmaceuticals (Nasdaq: DAWN)
Servier is acquiring Day One Biopharmaceuticals for $2.5B to expand its rare oncology pipeline. Discover what the deal means for pediatric cancer drug innovation.
Day One Biopharmaceuticals moves to acquire Mersana Therapeutics in $285m cancer-drug deal
Find out how Day One Biopharmaceuticals’ $285 million acquisition of Mersana Therapeutics could reshape the rare-cancer ADC landscape today.
Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors
Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two…